Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNO-863
- Development stage
- Unknown
- Lead developer
- MoonBio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MNO-863 is an investigational live biotherapeutic product (LBP) consisting of the bacterial strain *Christensenella intestinihominis*, developed by Moon (Guangzhou) Biotech (MoonBio). It is being developed as a second-generation probiotic for the treatment of metabolic disorders, including obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH). The mechanism of action involves modulating the gut microbiome to increase the abundance of short-chain fatty acid (SCFA)-producing bacteria. These SCFAs subsequently induce the secretion of intestinal hormones, specifically glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), which help regulate glucose metabolism, insulin resistance, and satiety. MNO-863 has received IND approval from the FDA for obesity and is currently in Phase 1 clinical development for multiple metabolic indications.
- Other names
- Christensenella intestinihominis
02
Targets
Beyond the preview
Go deeper on MNO-863.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNO-863.